Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of DNB-001 in Intraocular Hypertension
2006-003907-38Phase 2Terminated
- Sponsor
- Danube Pharmaceuticals
- Start
- Jan 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pediatric ocular hypertension and ocular hypertension comparing DNB-001 twice daily with Placebo twice daily (2 arms). Primary endpoint: Primary efficacy endpoint: percentage change in intraocular pressure. Started Jan 2007; status: terminated.
02
Drugs
DNB-001
03
Conditions
pediatric ocular hypertensionocular hypertension
Beyond the preview
Go deeper on 2006-003907-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003907-38.